Robert W. Baird analyst Brian Skorney maintained a Buy rating on Neurocrine (NASDAQ:NBIX) on Wednesday, setting a price target of $117, which is approximately 28.51% above the present share price of $91.04.
Skorney expects Neurocrine to post earnings per share (EPS) of $0.00 for the second quarter of 2021.
The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in Neurocrine, with an average price target of $119.15.
The analysts price targets range from a high of $163 to a low of $98.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $236.6 million and a net profit of $31.5 million. The company's market cap is $8.61 billion.
According to TipRanks.com, Robert W. Baird analyst Brian Skorney is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.5% and a 49.40% success rate.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.